#Sweden #Copenhagen #Lecanemab #Eisai #BioArctic

Lecanemab Presentation at AD/PD 2026

BioArctic, in collaboration with Eisai, will present crucial findings on its Alzheimer’s treatment, lecanemab, at the 2026 AD/PD Congress in Copenhagen and online. Taking place from March 17 to 21, this prestigious event will feature an oral presentation by BioArctic co-founder Professor Lars Lannfelt and their poster presentation on exidavnemab.

Latest Findings on Lecanemab

The agenda includes detailed explorations of real-world efficacy and safety data, particularly highlighting the four-year findings from the Clarity AD Open-Label Extension trial. These findings are pivotal, given the ongoing global concerns regarding Alzheimer’s disease and the increasing need for effective treatments.

Eisai will also conduct an industry-sponsored symposium to foster discussions around the early interventions in Alzheimer’s disease. This discussion is especially relevant as the disease has significant implications on global healthcare systems and families.

Oral Presentations

The sessions regarding lecanemab will cover a variety of subjects:

• - Real-world outcomes and mechanistic insights in anti-amyloid treatments: This presentation discusses the safety and effectiveness of lecanemab, particularly focusing on patients who are APOE4 homozygous. This analysis supports the understanding of which patients may benefit most from lecanemab's treatment.

• - Mechanisms of action and binding profile: These sessions aim to provide insights into how lecanemab interacts at the biological level, offering vital clues about its efficacy in Alzheimer’s treatment.

Poster Presentations

Moreover, posters displayed during the congress will delve into:

• - 48-Month Results for APOE E4 Non-Carriers and Heterozygotes: Highlighting long-term data for those with varying APOE4 statuses, this information aims to shed light on the effectiveness of lecanemab across diverse patient groups.

• - Correlation Studies: Research demonstrating how lecanemab reduces specific Alzheimer’s disease-associated biomarkers will also be highlighted, showcasing its potential to alter disease progression meaningfully.

The collaborative efforts between BioArctic and Eisai have been instrumental since the beginning of their partnership in 2005, with a shared commitment to addressing Alzheimer’s using innovative solutions. Lecanemab’s development was sparked by Professor Lannfelt's discovery of the Arctic mutation in Alzheimer’s, demonstrating the critical link between research and therapeutic application.

About BioArctic and Lecanemab

BioArctic is at the forefront of biopharmaceutical innovation, focusing on treatments that could potentially delay or halt neurodegenerative diseases. Lecanemab, branded as Leqembi, is distinguished as a monoclonal antibody aimed at combating Alzheimer's, showcasing how scientific advancements lead to practical disease management solutions.

The treatment has gained regulatory approval in 53 countries, a testament to its groundbreaking approach and the need for solutions in this demanding field of healthcare.

To summarize, the upcoming AD/PD 2026 congress serves as a critical platform for discussing long-term data on lecanemab, offering hope for those affected by Alzheimer’s disease and their families. The insights gained from these presentations could be pivotal in shaping future Alzheimer’s treatment strategies, enhancing patient outcomes on a global scale.